Table 2.

Random effects model Bayesian network meta-analysis of estimated HR values for PFS^#1 between different treatment regimens.

Endo	0.65 (0.39, 1.06)	0.69 (0.45, 1.05)	0.38 (0.16, 0.88)	0.45 (0.23, 0.89)
1.55 (0.94, 2.55)	Her2-tki+Endo	1.06 (0.64, 1.76)	0.58 (0.25, 1.41)	0.69 (0.38, 1.28)
1.46 (0.95, 2.24)	0.94 (0.57, 1.55)	Her2-mAb+Endo	0.55 (0.27, 1.13)	0.65 (0.35, 1.21)
2.66 (1.14, 6.14)	1.71 (0.71, 4.06)	1.82 (0.88, 3.71)	Her2-mAb+Her2-mAb+Endo	1.19 (0.46, 3.05)
2.23 (1.13, 4.39)	1.44 (0.78, 2.63)	1.53 (0.83, 2.82)	0.84 (0.33, 2.16)	Her2-mAb+Her2-tki+Endo

Note: The estimated HR and 95%CrI for PFS^#1 between treatment regimens are shown in the table above, with the lower left corner representing each column treatment group compared to each row treatment group, and the opposite in the upper right corner. HR < 1 indicates that the column treatment regimen prolongs PFS compared to the row treatment regimen; HR > 1 indicates that the column treatment regimen has a poorer benefit on PFS compared to the row treatment regimen. Significant differences between the two groups are shown in bold. (PFS: progression free survival; HR: hazard ratio; CrI: credible interval).